Identification of TMEM106B as a Shared Potential Drug Target for Depression and Stroke Through Comprehensive Genetic

Wenqiang Zhang1,2,3, Lingli Qiu3, Yunjie Liu3

  • 1Jiangxi Provincial Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

Depression and Anxiety
|September 15, 2025
PubMed

Insights

This study reveals a shared genetic basis between depression and stroke, suggesting depression intervention may help prevent strokes. Key genes like TMEM106B and FES are implicated, with depression causally linked to stroke risk.

Area of Science:

  • Genetics
  • Neuroscience
  • Public Health

Background:

  • The link between depression and stroke is well-known but not fully understood genetically.
  • Investigating shared genetic factors can inform primary stroke prevention strategies.

Purpose of the Study:

  • To explore the shared genetic etiology and causal relationship between depression and stroke.
  • To determine if depression intervention can serve as a primary stroke prevention method.

Main Methods:

  • Utilized large-scale genome-wide association studies (GWAS) for depression and stroke in European individuals.
  • Employed linkage-disequilibrium score regression, SUPERGNOVA, cross-trait meta-analysis, transcriptome-wide association study (TWAS), and Mendelian randomization (MR).

Main Results:

  • Significant positive global genetic correlation (rg=0.18, p=2.92×10⁻⁹) found between depression and stroke.
  • Identified shared genetic loci (TMEM106B, FES) and a genomic region (11q23.2) with local genetic correlation.
  • Mendelian randomization indicated a causal effect of depression on stroke (OR=1.13), mediated by smoking, hypertension, type 2 diabetes, and atrial fibrillation.
  • Drug target MR showed TMEM106B influences both depression and stroke risk.

Conclusions:

  • Highlights a shared genetic basis and a causal link between depression and stroke.
  • Suggests depression intervention as a potential primary prevention strategy for stroke.
  • Provides insights into biological mechanisms, including lysosome localization and specific genes.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...